Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil

The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida Lima, Karoline, Osawa, Isabeli Yumi Araújo, Ramalho, Maria Carolina Clares, de Souza, Izadora, Guedes, Camila Banca, de Souza Filho, Cláudio Henrique Dahne, Monteiro, Linda Karolynne Seregni, Latancia, Marcela Teatin, Rocha, Clarissa Ribeiro Reily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136186/
https://www.ncbi.nlm.nih.gov/pubmed/37189700
http://dx.doi.org/10.3390/biomedicines11041081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136186/
https://www.ncbi.nlm.nih.gov/pubmed/37189700
http://dx.doi.org/10.3390/biomedicines11041081

Ejemplares similares